Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome

• Published in: Journal of viral hepatitis Vol. 28; no. 2; pp. 302 - 316
• Main Authors: Fahnøe, Ulrik, Pedersen, Martin S., Sølund, Christina, Ernst, Anja, Krarup, Henrik B., Røge, Birgit T., Christensen, Peer B., Laursen, Alex L., Gerstoft, Jan, Thielsen, Peter, Madsen, Lone G., Pedersen, Anders G., Schønning, Kristian, Weis, Nina, Bukh, Jens
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-02-2021
• Subjects: Antiviral agents; Chronic infection; Cirrhosis; direct‐acting antivirals; Disease resistance; DNA helicase; genome‐wide association studies; Genotype & phenotype; Genotypes; Hepatitis C; hepatitis C virus; Liver cirrhosis; Mutation; next‐generation sequencing; Population decline; resistance‐associated substitution; treatment failure; Viremia; hepatitis C virus; resistance-associated substitution; next-generation sequencing; treatment failure; genome-wide association studies; direct-acting antivirals
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.13430

Direct‐acting antivirals (DAAs) have proven highly effective against chronic hepatitis C virus (HCV) infection. However, some patients experience treatment failure, associated with resistance‐associated substitutions (RASs). Our aim was to investigate the complete viral coding sequence in hepatitis C patients treated with DAAs to identify RASs and the effects of treatment on the viral population. We selected 22 HCV patients with sustained virologic response (SVR) to match 21 treatment‐failure patients in relation to HCV genotype, DAA regimen, liver cirrhosis and previous treatment experience. Viral‐titre data were compared between the two patient groups, and HCV full‐length open reading frame deep‐sequencing was performed. The proportion of HCV NS5A‐RASs at baseline was higher in treatment‐failure (82%) than matched SVR patients (25%) (p = .0063). Also, treatment failure was associated with slower declines in viraemia titres. Viral population diversity did not differ at baseline between SVR and treatment‐failure patients, but failure was associated with decreased diversity probably caused by selection for RAS. The NS5B‐substitution 150V was associated with sofosbuvir treatment failure in genotype 3a. Further, mutations identified in NS2, NS3‐helicase and NS5A‐domain‐III were associated with DAA treatment failure in genotype 1a patients. Six retreated HCV patients (35%) experienced 2nd treatment failure; RASs were present in 67% compared to 11% with SVR. In conclusion, baseline RASs to NS5A inhibitors, but not virus population diversity, and lower viral titre decline predicted HCV treatment failure. Mutations outside of the DAA targets can be associated with DAA treatment failure. Successful DAA retreatment in patients with treatment failure was hampered by previously selected RASs.